Malta - English - Malta Medicines Authority

ebewe pharma gmbh nfg. kg mondseestrasse 11, 4866 unterach, austria - docetaxel - concentrate for solution for infusion - docetaxel 10 mg/ml - antineoplastic agents

Israel - English - Ministry of Health

a.l. medi-market ltd. - docetaxel anhydrous - concentrate for solution for infusion - docetaxel anhydrous 20 mg / 1 ml - docetaxel - breast cancer : docetaxel seacross 20 mg/ml in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer .docetaxel seacross 20 mg/ml in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition .docetaxel seacross 20 mg/ml monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent .docetaxel seacross 20 mg/ml in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease .docetaxel seacross 20 mg/ml in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. doxorubicin and cyclophosphamide followed by docetaxel seacross 20 mg/ml in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer .docetaxel seacross 20 mg/ml in combination with trastuzumab, and carboplatin (tch) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer.non-small cell lung cancer : docetaxel seacross 20 mg/ml is indicated for the treatment of patients with advanced non-small cell lung carcinoma. ovarian cancer : docetaxel seacross 20 mg/ml is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy .prostate cancer : docetaxel seacross 20 mg/ml in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer . esophageal cancer : docetaxel seacross 20 mg/ml for the treatment of esophageal cancer.gastric cancer : docetaxel seacross 20 mg/ml for the treatment of advanced gastric cancer.head and neck (scchn): docetaxel seacross 20 mg/ml as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.docetaxel seacross 20 mg/ml in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; ethanol absolute; polysorbate 80 - breast cancer. metastatic breast cancer. treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.. adjuvant treatment of breast cancer. docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node positive breast cancer.. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of greater than or equal to 1 cm and less than 7 cm.. non-small cell lung cancer. treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum based chemotherapy.. ovarian cancer. treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.. prostate cancer. treatment of patients with androgen independent (hormone refractory) prostate cancer.. head and neck cancer. docetaxel, in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; ethanol absolute; polysorbate 80 - breast cancer. metastatic breast cancer. treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.. adjuvant treatment of breast cancer. docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node positive breast cancer.. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of greater than or equal to 1 cm and less than 7 cm.. non-small cell lung cancer. treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum based chemotherapy.. ovarian cancer. treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.. prostate cancer. treatment of patients with androgen independent (hormone refractory) prostate cancer.. head and neck cancer. docetaxel, in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; ethanol absolute; polysorbate 80 - breast cancer. metastatic breast cancer. treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.. adjuvant treatment of breast cancer. docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node positive breast cancer.. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of greater than or equal to 1 cm and less than 7 cm.. non-small cell lung cancer. treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum based chemotherapy.. ovarian cancer. treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.. prostate cancer. treatment of patients with androgen independent (hormone refractory) prostate cancer.. head and neck cancer. docetaxel, in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; ethanol absolute; polysorbate 80 - breast cancer. metastatic breast cancer. treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.. adjuvant treatment of breast cancer. docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node positive breast cancer.. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.. docetaxel in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2.. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of greater than or equal to 1 cm and less than 7 cm.. non-small cell lung cancer. treatment of patients with locally advanced or metastatic non-small cell lung cancer, including those who have failed platinum based chemotherapy.. ovarian cancer. treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.. prostate cancer. treatment of patients with androgen independent (hormone refractory) prostate cancer.. head and neck cancer. docetaxel, in combination with cisplatin and fluorouracil, is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Canada - English - Health Canada

sandoz canada incorporated - docetaxel - solution - 10mg - docetaxel 10mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

northstar rxllc - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel anhydrous 20 mg in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - docetaxel, quantity: 10 mg/ml - injection - excipient ingredients: polysorbate 80; propylene glycol; disodium edetate; ethanol; citric acid

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - docetaxel, quantity: 10 mg/ml - injection - excipient ingredients: polysorbate 80; propylene glycol; disodium edetate; ethanol; citric acid